HOME >> MEDICINE >> NEWS
Iressa news backgrounder

It is a drug suffused in promise, a next-generation therapy that has shown glimmers of powerful potential. Iressa is the kind of treatment that oncologists dream of - a pill that can be swallowed once a day, a non-toxic therapy that causes few side effects. For 10 percent of patients who have tried it, people who have no other options left for them, Iressa seems to make the difference between life and death. Another 30 percent to 40 percent of patients who have used the drug have a better, if not a longer, life.

But for most patients, Iressa does not shrink their cancer. That fact has become a challenge to researchers at The University of Texas M. D. Anderson Cancer Center. They are dedicated to solving the central puzzle that Iressa, and similar other targeted therapies, pose - what are the cancers that may best respond, and which patients will benefit?

M. D. Anderson researchers have been at the forefront of testing Iressa, as well as a slew of other experimental drugs that target critical cancer cell pathways. They have been involved in all phases of clinical trials looking at the effectiveness of Iressa in common lung cancer, work that helped lead to federal Food and Drug Administration approval of the drug in early 2003 for use when standard therapy has not helped lung cancer patients.

Now, investigators at M. D. Anderson are testing Iressa in malignant brain cancer and are poised to study it in a number of cancers, including head and neck, breast, and prostate, along with further investigations in lung cancer.

"M. D. Anderson is one of the leading institutions in developing targeted therapies such as Iressa," says Frank Fossella, M.D., professor in the Department of Thoracic/Head and Neck Medical Oncology, who has treated many lung and other head and neck cancers where it has shown tantalizing benefit.

"So far, Iressa has been a good news, bad news story. The response rates are not as high as we would have liked
'"/>

Contact: Nancy Jensen
nwjensen@mdanderson.org
713-792-0655
University of Texas M. D. Anderson Cancer Center
16-Oct-2003


Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Gene mutations predict which lung cancers will respond to Iressa
2. Iressa news backgrounder: Testing of smart drug expands at M. D. Anderson Cancer Center
3. Chemoprevention backgrounder: Working for a future of cancer chemoprevention
4. Cancer gene therapy news backgrounder: New ideas fuel next generation gene therapy research
5. Cancer markers news backgrounder: Future of cancer diagnosis, treatment lies in tumor barcode

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Iressa news backgrounder

(Date:9/4/2015)... ... 2015 , ... Steven Winter Associates, Inc., (SWA) is pleased ... for the Residential Award of Merit by the Connecticut Green Building Council (CTGBC) ... highly competitive field of submissions, the net-zero energy residence will be honored at ...
(Date:9/4/2015)... ... 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has written ... the Pope’s upcoming trip to the United States. , Yisrayl lays out what he says ... Vatican and society is. Yisrayl also provides the meaning of his own name and describes ...
(Date:9/4/2015)... ... September 04, 2015 , ... EMED Jamaica Global ... that it has entered into a multi-year agreement with Health City Cayman Islands. ... the link between American healthcare, Jamaican healthcare and Health City Cayman Islands to ...
(Date:9/3/2015)... WI (PRWEB) , ... September 04, 2015 , ... ... month of September. , "There are so many children and adults who don't ... Wisconsin," says Dr. Sara Mahalko-Leonhardt. "We love holding our annual Coat Drive to help ...
(Date:9/3/2015)... ... September 03, 2015 , ... Allied Anesthesia is proud to ... is the norm not the exception. , St. Jude was recently named one of ... Stroke Association, making it one of only 10 hospitals in the state to earn ...
Breaking Medicine News(10 mins):Health News:South Glastonbury Home Selected for Award by Connecticut Green Building Council 2Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 2Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 3Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 4Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 5Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 6Health News:AlignLife is Helping to Keep the Community Warm This Winter 2Health News:Allied Anesthesia Physicians Announce Partnership with St. Jude 2Health News:Allied Anesthesia Physicians Announce Partnership with St. Jude 3
(Date:9/4/2015)... , Sept. 4, 2015  PTC Therapeutics, ... announce five recipients of its first-ever global awards ... Vision and Empowerment), designed to aid nonprofit organizations ... dystrophy (DMD) community. The announcement is made as ... World Duchenne Awareness Day on Monday, September 7, ...
(Date:9/4/2015)... , September 4, 2015 ... ), a clinical-stage pharmaceutical company focused on the development ... Company will participate in the upcoming Rodman & Renshaw ... September 8-10, 2015 in New York City ... Oramed, will present a corporate overview on September 9, ...
(Date:9/4/2015)... , September 4, 2015 Future ... Allergic Rhinitis drugs - new ... Where is the market for allergic rhinitis drugs ... Visiongain ,s new report shows you potential revenues ... prospects. Our 326 page report provides 273 ...
Breaking Medicine Technology:PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 2PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 3PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 4Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7
Cached News: